Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EPS (Basic) (2016 - 2025)

Acro Biomedical has reported EPS (Basic) over the past 10 years, most recently at $0.0 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was -$0.0 (down 139.13% YoY), and the annual figure for FY2025 was -$0.0, down 139.13%.
  • EPS (Basic) for Q4 2025 was $0.0 at Acro Biomedical, up from -$0.0 in the prior quarter.
  • Over the last five years, EPS (Basic) for ACBM hit a ceiling of $0.0 in Q4 2025 and a floor of -$0.07 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.0 (2025), compared with a mean of -$0.03.
  • Biggest five-year swings in EPS (Basic): crashed 5312.25% in 2021 and later surged 498.44% in 2025.
  • Acro Biomedical's EPS (Basic) stood at -$0.07 in 2021, then increased by 4.56% to -$0.07 in 2022, then soared by 99.55% to -$0.0 in 2023, then surged by 41.49% to -$0.0 in 2024, then surged by 498.44% to $0.0 in 2025.
  • The last three reported values for EPS (Basic) were $0.0 (Q4 2025), -$0.0 (Q3 2025), and -$0.0 (Q2 2025) per Business Quant data.